A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

European Journal of Clinical Pharmacology

Volumn 60, Issue 11, 2005, Pages 779-784

  Hassan Alin, M ^a   Andersson, T ^b   Niazi, M ^a   Rohss K ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Pharmacokinetics; R omeprazole; Racemic omeprazole; S omeprazole

Indexed keywords

OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HUMANS; MALE; OMEPRAZOLE; STEREOISOMERISM; TIME FACTORS;

EID: 15444373208     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0841-1     Document Type: Article

References (15)

1. AstraZeneca, Data on File
2. Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:96-972
3. Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L (2000) Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (RO). Gastroenterology 118(4 Pt II):A1210
4. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L (2001) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40(6):411-426
5. Lagerström PO, Persson BA (1984) Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 309:347-356
6. Andersson T (1991) Pharmacokinetics of omeprazole in man; with special reference to single and repeated administration, drug interactions and polymorphic metabolism. Thesis, Göteborg University, ISBN 91-628-0180-5
7. Hassan-Alin M, Andersson T, Bredberg E, Röhss K (2000) Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 56:665-670
8. Andersson T, Cederberg C, Heggelund A, Lundborg P (1991) The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 3:45-52
9. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole. Clin Pharmacol Ther 47:79-85
10. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530
11. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37:597-604
12. Junghard Ola, Hassan-Alin Mohammed, Hasselgren G (2000) The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH (abstract 331). Gastroenterology 118 (4 Pt II):A17
13. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 24:270-276
14. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K (2000) Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux diseases. Aliment Pharmacol Ther 14:861-867
15. Hunt RH (1999) Importance of pH control in the management of GERD. Arch Intern Med 159:649-57